Inter city tales - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inter city tales


Pharmaceutical Technology Europe
Volume 23, Issue 5


Rich Whitworth
As I strolled through Times Square, famous brand coffee cup in hand, towards the Jacob K. Javits Convention Center in New York, my thoughts were entirely focused on Interphex. As I sit here, typing this, I realise that the Interpack event in Dusseldorf looms large. And I am constantly aware of the fact that we are interconnected at all times thanks to the interweb (as my father says). "Inter" has become an important word for us, but what does it mean?

Well, turns out it's all about sharing.

At Interphex, so much valuable information and intelligence was divulged to expectant delegates. One particular stand out for me was a unified message from not one but two officials that the FDA fully supports continuous manufacturing. Watch this space for forthcoming articles on this very topic. It seems that 'missing out' on this sort of information is what drives our thirst to visit such exhibitions, make new contacts and join salient groups on LinkedIn (other networking tools are available!).

What can be shared and, thus, what can be learned?

No doubt Interpack will provide enormous amounts of potential in this vein, spanning multiple industries as it does. I hope to share the experience with some of our readers—you know who you are!

Here at Pharmaceutical Technology Europe, sharing is becoming more and more important for us. Peer reviews are a staple of our publication and within these covers you will find three such articles, all delivering strong insight on diverse topics. This has only been made possible by working more closely with Pharmaceutical Technology in North America. And I would like to take this opportunity to thank them for their continued support and ethic of sharing.

What this means to you, dear reader, is that our scope for sharing industry knowledge has widened significantly. All peer reviewed articles will now be published simultaneously in both PTE and PT — especially great if you happen to be the author. Our hope is that this move will aid the pharma industry by connecting you, the people in that industry, to what's happening on a scientific level around the world.

Please feel free to share your thoughts directly with me at
or with other likeminded readers on LinkedIn ( http://www.pharmtech.com/linkedin).

Best wishes,
Rich Whitworth, Editor

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here